Optimum Antithrombotic Therapy in Patients Requiring Long-Term Anticoagulation and Undergoing Percutaneous Coronary Intervention

Table 1

Baseline characteristics of trials comparing dual therapy with triple therapy after PCI.

Study/author	Design	Year	Number of patients	Male (%)	TT	DT	Follow-up (months)	Indication for PCI	INR	Indication for anticoagulation
RE-DUAL PCI [31]	RCT	2017	2725	76%	w + a + c, w + a + t	+ (c or t) [44%], d + (c or t) [56%]	14	ACS, CAD	2.0–3.0	AF
De Vecchis et al. [33]		2016	98	45%	w + a + c	w + c [NR], w + a [NR]	12	ACS, CAD	NR	AF, mechanical valve, VTE, dilated cardiomyopathy
PIONEER [12]	RCT	2016	1415	74%	w + a + c [96%], w + a + p [1%], w + a + t [3%]	R + c [93%], R + p [2%], R + t [5%]	12	ACS, CAD	2.0–3.0	AF
ORBIT-AF [34]		2016	1827	72%	w + a + c, w + a + p, d + a + c, d + a + p	w + a [NR], w + c [NR], w + p [NR], d + a [NR], d + c [NR], d + p [NR]	24	CAD	NR	AF
AFCAS [24]		2014	914	70%	w + a + c	w + c [100%]	12	ACS, CAD	1.8–3	AF
WARSTENT [25]		2014	401	26%	w + a + c	w + c [NR], w + a [NR]	12	ACS, CAD	1.8–4.5	AF, apical thrombus, apical akinesis, VTE, mechanical valve
Braun et al. [35]		2015	266	77%	w + a + c	w + t [100%]	3	ACS	2.0–3.0	AF, apical thrombus, apical akinesis, VTE, mechanical valve
Lamberts et al. [36]		2013	12165	61%	w + a + c	w + c [27%], w + a [73%]	12	ACS, CAD	NR	AF
WOEST [9]	RCT	2013	573	80%	w + a + c	w + c [100%]	12	ACS, CAD	2	AF, mechanical valve, VTE, apical aneurysm, PAD, EF < 30%
Rubboli et al. [37]		2012	632	73%	w + a + c	w + a [100%]	12	ACS, CAD	NR	AF, VTE, mechanical valve, dilated cardiomyopathy, ischemic heart disease, cardiac thrombus, CVA, LV aneurysm, biological heart valve
Persson et al. [38]		2011	1177	76%	w + a + c	w + c [45%], w + a [55%]	12	ACS	NR	NR
Gao et al. [39]		2010	622	71%	w + a + c	w + c [87%] or w + a [13%]	12	ACS, CAD	1.8–2.5	AF
MUSICA [40]		2009	405	81%	w + a + c, LMWH + a + c	w + c [80%], LMWH + c [4%], w + a [13%], LMWH + a [2%]	6	ACS, CAD	NR	AF, mechanical valve, CVA
Sørensen et al. [41]		2009	40812	63%	w + a + c	w + c [0.5%], w + a [2%]	18	ACS	NR	NR
GRACE [26]		2007	800	70%	w + a + c	w + c [51%], w + a [49%]	6	ACS	NR	AF, STEMI, VTE, mechanical valve
Karjalainen et al. [42]		2007	239	74%	w + a + c	w + c [58%], w + a [42%]	12	ACS, CAD	2–2.5	AF, mechanical valve, VTE, CVA

a = aspirin; ACS = acute coronary syndrome; AF = atrial fibrillation; c = clopidogrel; CAD = coronary artery disease; CVA = cerebral vascular accident; d = dabigatran (110 mg BID); = dabigatran (150 mg BID); DT = dual therapy; LMWH = low molecular weight heparin; NR = not reported; p = prasugrel; = prospective trial; PAD = peripheral artery disease; R = rivaroxaban; = retrospective trial; RCT = randomized-control trial; t = ticagrelor; TT = triple therapy; VTE = venous thromboembolism.